Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. …

Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary function ...
Fierce Biotech

Transforming neurodegenerative disease treatment

Cognition Therapeutics, led by CEO Lisa Ricciardi, is on a mission to change the course of neurodegenerative diseases. | ...
Aerospace Manufacturing and Design

Reactive oligomer for tough, lightweight aerospace composites

SABIC launches ULTEM SU3102P reactive oligomer, a toughening agent for thermoset composites used in primary and secondary ...
precisionmedicineonline

Dyne Starts Phase III DMD Exon Skipping Therapy Trial as It Anticipates BLA Filing

NEW YORK – Dyne Therapeutics is beginning a Phase III trial of its therapy, zeleciment rostudirsen (z-rostudirsen), for Duchenne muscular dystrophy patients amenable to exon 51 skipping ahead of ...